This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Former Johnson & Johnson And Bausch & Lomb Executive, Gerald Ostrov, Joins Oramed Pharmaceuticals' Board Of Directors

JERUSALEM, October 18, 2012 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (, a developer of oral drug delivery systems, announced today that Gerald Ostrov, former top executive of Johnson & Johnson and Bausch & Lomb, joined its board as Director.

Mr. Ostrov has a long history of excellence and innovative thinking within the Pharmaceutical, Medical Device, and Consumer sectors. He began his career with Johnson & Johnson in their Health Care Division in 1976. After leaving the company for almost a decade to assume top executive roles for Ciba-Geigy Consumer Pharmaceuticals Company (which went on to merge with Sandoz in 1996 to become the pharmaceutical giant Novartis), Mr. Ostrov returned to Johnson & Johnson in 1991 to serve as President of Consumer & Personal Care Products Unit. Within a few years he was promoted to Company Group Chairman and became responsible for all Consumer and Personal Care businesses in North America shortly thereafter.

Beginning in 1998 until his retirement in 2006, Mr. Ostrov very successfully served as Company Group Chairman for Johnson & Johnson's Worldwide Vision Care businesses. He came out of retirement in 2008 to serve as Chairman and CEO of Bausch & Lomb until 2010. During his appointment as CEO, Mr. Ostrov assisted in the stabilization and streamlining of the company's business component following its privatization by private equity investors. He increased operating profit and cash flow via his focus on creating an innovative pipeline to ensure long term value, and decreased cost while improving quality.

"We are very pleased that Gerald has joined Oramed's Board of Directors. He brings much leadership experience and vision to the table, and we trust in his ability to contribute to Oramed's business model and long-term goals for establishing the company's pipeline on a global scale."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs